US · Healthcare · Biotechnology
EPS came in at -0.11 against a street estimate of -0.10 — a miss of 10.0%.
Analysts rate Taysha Gene Therapies Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $13.25.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 7.36% |
| The Goldman Sachs Group Inc | 6.99% |
| venBio Select Advisor LLC | 6.78% |
| BlackRock Inc | 5.74% |
| Vestal Point Capital LP | 5.63% |
| Morgan Stanley - Brokerage Accounts | 5.62% |
| FMR Inc | 4.48% |
| RTW INVESTMENTS, LLC | 4.28% |
| Document | Date |
|---|---|
| Material agreement · Q2 2026 | 2026-06-25 |
| Reg FD disclosure · Q2 2026 | 2026-06-22 |
| Shareholder vote results · Q2 2026 | 2026-06-02 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-22 |
| Annual report FY2025 | 2026-03-19 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Taysha Gene Therapies Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.